LINGO2

Summary

LINGO2 (leucine rich repeat and Ig domain containing 2, HGNC:21207) is a protein-coding gene on chromosome 9p21.2-p21.1, encoding Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 2 (Q7L985).

Predicted to act upstream of or within positive regulation of synapse assembly. Predicted to be located in membrane. Predicted to be active in several cellular components, including extracellular space; glutamatergic synapse; and synaptic membrane.

Source: NCBI Gene 158038 — RefSeq curated summary.

At a glance

• GWAS associations: 71
• Clinical variants (ClinVar): 143 total
• MANE Select transcript: NM_001258282

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21207
Approved symbol	LINGO2
Name	leucine rich repeat and Ig domain containing 2
Location	9p21.2-p21.1
Locus type	gene with protein product
Status	Approved
Aliases	LERN3
Ensembl gene	ENSG00000174482
Ensembl biotype	protein_coding
OMIM	609793
Entrez	158038

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000379992, ENST00000493941, ENST00000698399, ENST00000698400, ENST00000698401, ENST00000698402, ENST00000698403, ENST00000698404, ENST00000698405

RefSeq mRNA: 4 — MANE Select: NM_001258282 NM_001258282, NM_001354574, NM_001354575, NM_152570

CCDS: CCDS6524

Canonical transcript exons

ENST00000698399 — 7 exons

Exon	Start	End
ENSE00001406659	28475940	28476025
ENSE00001408858	28670200	28670280
ENSE00001483298	27937617	27950706
ENSE00001483303	28295208	28295366
ENSE00001483304	28372836	28372868
ENSE00003973552	29212922	29213601
ENSE00003973554	28947818	28947914

Expression profiles

Bgee: expression breadth ubiquitous, 157 present calls, max score 97.87.

FANTOM5 (CAGE): breadth broad, TPM avg 1.9371 / max 129.1825, expressed in 484 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100367	0.7027	219
100365	0.4301	210
100369	0.4098	172
100366	0.2891	151
100364	0.0665	34
100368	0.0389	13

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.87	gold quality
oocyte	CL:0000023	94.71	gold quality
endothelial cell	CL:0000115	93.52	gold quality
middle temporal gyrus	UBERON:0002771	87.36	gold quality
Brodmann (1909) area 23	UBERON:0013554	85.48	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.01	gold quality
kidney epithelium	UBERON:0004819	81.39	gold quality
buccal mucosa cell	CL:0002336	81.15	silver quality
primary visual cortex	UBERON:0002436	79.52	gold quality
cortical plate	UBERON:0005343	78.60	gold quality
cauda epididymis	UBERON:0004360	78.25	gold quality
myometrium	UBERON:0001296	76.20	gold quality
body of uterus	UBERON:0009853	76.13	gold quality
sperm	CL:0000019	75.88	silver quality
occipital lobe	UBERON:0002021	75.49	gold quality
cardiac muscle of right atrium	UBERON:0003379	74.92	gold quality
left ventricle myocardium	UBERON:0006566	74.66	gold quality
entorhinal cortex	UBERON:0002728	74.26	gold quality
islet of Langerhans	UBERON:0000006	74.19	gold quality
Brodmann (1909) area 46	UBERON:0006483	73.77	gold quality
myocardium	UBERON:0002349	73.58	gold quality
cerebellar vermis	UBERON:0004720	73.11	silver quality
prefrontal cortex	UBERON:0000451	72.05	gold quality
superior frontal gyrus	UBERON:0002661	71.60	gold quality
smooth muscle tissue	UBERON:0001135	71.25	gold quality
frontal cortex	UBERON:0001870	70.11	gold quality
tibialis anterior	UBERON:0001385	69.66	silver quality
neocortex	UBERON:0001950	69.27	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	68.70	gold quality
cerebral cortex	UBERON:0000956	67.91	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-180759	yes	4135.93
E-HCAD-35	yes	3099.83
E-HCAD-25	yes	91.27
E-ANND-3	yes	4.38

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

88 targeting LINGO2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-567	99.63	68.57	1219
HSA-MIR-802	99.61	67.70	1254
HSA-MIR-6832-5P	99.58	64.82	1132
HSA-MIR-6758-3P	99.57	67.55	1078
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-4708-3P	99.51	67.99	870

Literature-anchored findings (GeneRIF, showing 7)

• LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease (PMID:20369371)
• demonstrated for the first time that rs7033345 is associated with PD and ET and rs10812774 with ET among Asians, suggesting that LINGO2 might act as a susceptibility gene for essential tremor and Parkinson’s disease (PMID:21287203)
• The results of this study concluded that the LINGO-2 variant rs109668280 does not contribute to the risk of developing parkinson disreas in Taiwan. (PMID:22123311)
• Data indicate that rs10968576, an intronic single nucleotide polymorphism (SNP) within the leucine rich repeat and Ig domain containing 2 LINGO2 (LERN3, LRRN6C) gene was associated with body mass in elderly Swedes at age 70. (PMID:25711307)
• LINGO2 rs824248 may serve as a susceptibility marker for gestational diabetes mellitus in Chinese females. (PMID:30426492)
• These indicate the involvement of LINGO2 in gastric cancer initiation and progression by altering cell motility, stemness, and tumorigenicity. (PMID:30696080)
• Variations in the LINGO2 and GLIS3 Genes and Gene-Environment Interactions Increase Gestational Diabetes Mellitus Risk in Chinese Women. (PMID:38888423)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	lingo2b	ENSDARG00000069970
danio_rerio	lingo2a	ENSDARG00000074535
mus_musculus	Lingo2	ENSMUSG00000045083
rattus_norvegicus	Lingo2	ENSRNOG00000005634

Paralogs (25): SLITRK3 (ENSG00000121871), LRFN3 (ENSG00000126243), LRFN1 (ENSG00000128011), SLIT2 (ENSG00000145147), LRFN2 (ENSG00000156564), LRRC38 (ENSG00000162494), SLITRK5 (ENSG00000165300), LRFN5 (ENSG00000165379), LRTM2 (ENSG00000166159), LINGO1 (ENSG00000169783), LRRN2 (ENSG00000170382), LRRN3 (ENSG00000173114), LRFN4 (ENSG00000173621), LRRN1 (ENSG00000175928), SLITRK1 (ENSG00000178235), GP5 (ENSG00000178732), SLITRK4 (ENSG00000179542), LRRC55 (ENSG00000183908), SLIT3 (ENSG00000184347), SLITRK6 (ENSG00000184564), SLITRK2 (ENSG00000185985), LRRC70 (ENSG00000186105), SLIT1 (ENSG00000187122), TLR9 (ENSG00000239732), TPBGL (ENSG00000261594)

Protein

Protein identifiers

Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 2 — Q7L985 (reviewed: Q7L985)

Alternative names: Leucine-rich repeat neuronal protein 3, Leucine-rich repeat neuronal protein 6C

All UniProt accessions (2): Q7L985, A0A8V8TNG1

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

RefSeq proteins (4): NP_001245211, NP_001341503, NP_001341504, NP_689783 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050541	LRR_TM_domain-containing	Family

Pfam: PF00560, PF07679, PF13855

UniProt features (28 total): repeat 12, glycosylation site 5, domain 3, topological domain 2, signal peptide 1, chain 1, disulfide bond 1, sequence variant 1, sequence conflict 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7L985-F1	85.02	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 432–483

Glycosylation sites (5): 38, 130, 188, 279, 327

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 70 (showing top): GOBP_SYNAPSE_ASSEMBLY, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_REGULATION_OF_SYNAPSE_ASSEMBLY, GOBP_POSITIVE_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_SYNAPSE_STRUCTURE_OR_ACTIVITY, GOBP_CELL_JUNCTION_ASSEMBLY, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS

GO Biological Process (1): positive regulation of synapse assembly (GO:0051965)

GO Molecular Function (2): signaling receptor activity (GO:0038023), protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), synaptic membrane (GO:0097060), glutamatergic synapse (GO:0098978), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synapse	2
synapse assembly	1
positive regulation of nervous system development	1
regulation of synapse assembly	1
positive regulation of cell junction assembly	1
molecular transducer activity	1
binding	1
membrane	1
cell periphery	1
plasma membrane region	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1434 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LINGO2	TFF3	Q07654	741
LINGO2	RTN4R	Q9BZR6	684
LINGO2	MOB3B	Q86TA1	607
LINGO2	TBPL1	P62380	598
LINGO2	MTIF3	Q9H2K0	584
LINGO2	POC5	Q8NA72	580
LINGO2	SEC16B	Q96JE7	571
LINGO2	TMEM160	Q9NX00	570
LINGO2	V9GXZ4	V9GXZ4	544
LINGO2	TNNI3K	Q59H18	530
LINGO2	ZNF608	Q9ULD9	517
LINGO2	DNAJC27	Q9NZQ0	515
LINGO2	GNPDA2	Q8TDQ7	513
LINGO2	QPCTL	Q9NXS2	507
LINGO2	NEGR1	Q7Z3B1	507
LINGO2	NUDT3	O95989	507

IntAct

9 interactions, top by confidence:

A	B	Type	Score
LINGO1	LINGO2	psi-mi:“MI:0915”(physical association)	0.560
LINGO2	GAPDHS	psi-mi:“MI:0914”(association)	0.530
SEMG2	VSIG8	psi-mi:“MI:0914”(association)	0.530
LINGO2	LGALS1	psi-mi:“MI:0914”(association)	0.530
LINGO1	PON2	psi-mi:“MI:0914”(association)	0.350
LINGO2	H1-1	psi-mi:“MI:0914”(association)	0.350

BioGRID (30): LINGO2 (Affinity Capture-MS), SMURF2 (Affinity Capture-MS), LGALS1 (Affinity Capture-MS), SLC34A2 (Affinity Capture-MS), GAPDHS (Affinity Capture-MS), PTPRD (Affinity Capture-MS), STK11IP (Affinity Capture-MS), LMAN2L (Affinity Capture-MS), TRIM11 (Affinity Capture-MS), CNPY3 (Affinity Capture-MS), CARKD (Affinity Capture-MS), LINGO2 (Affinity Capture-MS), SMURF2 (Affinity Capture-MS), STK11IP (Affinity Capture-MS), CARKD (Affinity Capture-MS)

ESM2 similar proteins: A0N0X6, A4IIW9, B0BLW3, B1H134, B1H234, B4F7C5, D3ZAL8, D3ZTV3, D4A7P2, E5DHB5, F1NUK7, F7D3V9, O43155, O43300, O94898, P58681, Q32Q07, Q3SXY7, Q3URE9, Q504C1, Q50L44, Q52KR2, Q5R482, Q5R6T0, Q5RDJ4, Q61809, Q66HV9, Q6RKD8, Q6UXK5, Q70AK3, Q7L985, Q80XG9, Q80ZD7, Q80ZD8, Q80ZD9, Q86VH4, Q86VH5, Q8BGA3, Q8BGT1, Q8BLU0

Diamond homologs: A0N0X6, A2AJ76, A2CG49, A4IGL7, A4IIW9, B3NS99, B4GBH0, B4HNW4, B4KPU0, B4MR28, B4P5Q9, B4QC63, G5EBF1, O75325, O95428, P0C6S8, P11627, P12960, P22063, P28685, P32004, P97924, Q02246, Q07409, Q09024, Q12860, Q290N5, Q32Q07, Q3UQ28, Q3URE9, Q3V1M1, Q5R482, Q61330, Q61809, Q62682, Q62845, Q63198, Q66HV9, Q69Z26, Q6AWJ9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

143 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	119
Likely benign	12
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

5332 predictions. Top by Δscore:

Variant	Effect	Δscore
9:27972142:G:C	donor_gain	1.0000
9:28015043:A:AC	donor_gain	1.0000
9:28058275:C:CT	acceptor_gain	1.0000
9:28295202:CCTTA:C	donor_loss	1.0000
9:28295203:CTTAC:C	donor_loss	1.0000
9:28295205:TAC:T	donor_loss	1.0000
9:28295207:C:A	donor_loss	1.0000
9:28475936:TTACC:T	donor_loss	1.0000
9:28475938:A:AC	donor_gain	1.0000
9:28475938:ACCA:A	donor_loss	1.0000
9:28475939:C:A	donor_loss	1.0000
9:28475939:C:CC	donor_gain	1.0000
9:27951675:G:C	donor_gain	0.9900
9:27972141:A:AC	donor_gain	0.9900
9:28014340:A:AC	donor_gain	0.9900
9:28058271:A:AC	acceptor_gain	0.9900
9:28058275:C:T	acceptor_gain	0.9900
9:28058276:A:T	acceptor_gain	0.9900
9:28067483:T:C	donor_gain	0.9900
9:28080857:T:A	donor_gain	0.9900
9:28260991:CCG:C	acceptor_gain	0.9900
9:28260992:C:T	acceptor_gain	0.9900
9:28260993:G:C	acceptor_gain	0.9900
9:28295362:CGAAC:C	acceptor_gain	0.9900
9:28295363:GAACC:G	acceptor_loss	0.9900
9:28295364:AACC:A	acceptor_loss	0.9900
9:28295365:ACCT:A	acceptor_loss	0.9900
9:28295366:CCT:C	acceptor_loss	0.9900
9:28295368:T:A	acceptor_loss	0.9900
9:28372834:ACC:A	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000000013 (9:28142146 A>T), RS1000000098 (9:28005993 T>C), RS1000002009 (9:27974029 T>C), RS1000003690 (9:28655388 C>T), RS1000004046 (9:28476743 C>G), RS1000008366 (9:28180237 C>A), RS1000008894 (9:28907322 T>C), RS1000009493 (9:28709654 T>G), RS1000010919 (9:29094896 C>A,T), RS1000015851 (9:28134680 G>C), RS1000015869 (9:28290299 C>A), RS1000016721 (9:28216549 A>G), RS1000018547 (9:29214075 C>T), RS1000021288 (9:28806739 T>C), RS1000022047 (9:28037875 A>G)

Disease associations

OMIM: gene MIM:609793 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): primary ovarian failure (MONDO:0005387), megacolon (MONDO:0001273)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

71 associations (top):

Study	Trait	p-value
GCST000763_10	Immunoglobulin A	9.000000e-06
GCST000830_9	Body mass index	3.000000e-13
GCST001762_297	Obesity-related traits	4.000000e-06
GCST001762_390	Obesity-related traits	7.000000e-06
GCST001762_522	Obesity-related traits	6.000000e-06
GCST001762_824	Obesity-related traits	2.000000e-06
GCST001953_16	Obesity	3.000000e-08
GCST001953_7	Obesity	2.000000e-10
GCST002218_3	Endometrial cancer	9.000000e-06
GCST002317_2	Type 2 diabetes	8.000000e-06
GCST002759_9	Motion sickness	6.000000e-15
GCST002783_4	Body mass index	1.000000e-11
GCST002783_407	Body mass index	2.000000e-14
GCST002783_533	Body mass index	7.000000e-14
GCST002783_83	Body mass index	5.000000e-06
GCST002885_3	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)	2.000000e-07
GCST003050_18	Schizophrenia	1.000000e-06
GCST003124_3	Mild influenza (H1N1) infection	9.000000e-13
GCST003125_3	Influenza A (H1N1) infection	2.000000e-10
GCST003855_3	Gut microbiota (bacterial taxa)	2.000000e-09
GCST003855_4	Gut microbiota (bacterial taxa)	3.000000e-08
GCST003986_18	Migraine	2.000000e-08
GCST004065_1	Waist circumference	1.000000e-11
GCST004065_57	Waist circumference	1.000000e-08
GCST004495_119	BMI (adjusted for smoking behaviour)	9.000000e-10
GCST004495_120	BMI (adjusted for smoking behaviour)	3.000000e-13
GCST004495_121	BMI (adjusted for smoking behaviour)	7.000000e-06
GCST004497_2	Body mass index (joint analysis main effects and smoking interaction)	1.000000e-11
GCST004497_3	Body mass index (joint analysis main effects and smoking interaction)	2.000000e-08
GCST004499_50	BMI in non-smokers	6.000000e-07

EFO canonical traits (21, from GWAS)

EFO ID	Trait name
EFO:0004747	protein measurement
EFO:0004340	body mass index
EFO:0003939	energy intake
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004627	IGF-1 measurement
EFO:0004230	endometrial neoplasm
EFO:0006928	motion sickness
EFO:0007635	concentration dose ratio
EFO:1001488	influenza A (H1N1)
EFO:0007874	gut microbiome measurement
EFO:0004318	smoking behavior
EFO:0008002	physical activity measurement
EFO:0007835	alcohol dependence measurement
EFO:0007681	triglyceride change measurement
EFO:0007660	neuroticism measurement
EFO:0009369	diffusing capacity of the lung for carbon monoxide
EFO:0006781	coffee consumption measurement
EFO:0004886	intracranial volume measurement
EFO:0008354	cognitive function measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0009819	comparative body size at age 10, self-reported

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008531	Megacolon	C06.405.469.158.701
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	8
Aflatoxin B1	decreases expression, decreases methylation, increases methylation, affects methylation	4
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Silicon Dioxide	decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
methyleugenol	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	increases methylation	1
trichostatin A	increases expression	1
sodium arsenite	affects splicing, decreases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Vorinostat	affects cotreatment, increases expression	1
Atrazine	decreases expression	1
Cadmium	decreases expression, increases abundance	1
Methamphetamine	affects response to substance	1
Methapyrilene	decreases methylation	1
Phthalic Acids	increases methylation	1
Tretinoin	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

77 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists